Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Phase I/II Study Evaluating MRG006A in Combination With Immune Checkpoint Inhibitors and Targeted Therapy in Patients With Advanced Hepatocellular Carcinoma

NCT07479485 is registered in ClinicalTrials.gov with Lepu Biopharma Co., Ltd. as lead sponsor.

NCT NCT07479485
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07479485 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Phase I/II Study Evaluating MRG006A in Combination With Immune Checkpoint Inhibitors and Targeted Therapy in Patients With Advanced Hepatocellular Carcinoma
Lead sponsor
Lepu Biopharma Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 8, 2026
Completion date
April 30, 2029
Enrollment
160 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma